Tags

Type your tag names separated by a space and hit enter

Weight management and current options in pharmacotherapy: orlistat and sibutramine.
Clin Ther. 2003 Jan; 25(1):58-80.CT

Abstract

BACKGROUND

Chronic obesity is associated with various cardiovascular disorders, including diabetes, dyslipidemia, and hypertension. Pharmacotherapy with antiobesity agents is an important management strategy in conjunction with lifestyle interventions.

OBJECTIVE

This article describes the pharmacologic management of obesity, concentrating on orlistat and sibutramine.

METHODS

Relevant articles were identified through a MEDLINE search (1966-February 2002) using the terms obesity, overweight, weight loss, antiobesity drugs, orlistat, and sibutramine. The search for efficacy trials was limited to randomized controlled studies of >6 months' duration. Also included in the review were relevant references cited in the bibliographies of identified articles, news reports, and the authors' own data.

RESULTS

Orlistat reduces fat absorption by inhibiting gastrointestinal lipases. In randomized, controlled trials of up to 2 years' duration, orlistat plus a hypocaloric diet produced significantly greater weight loss than placebo (P < 0.001). In the maintenance phase, patients taking orlistat had less weight regain than did placebo recipients. The weight reduction with orlistat was also associated with a significant improvement in control of cardiovascular risk factors (P < 0.05). Unlike orlistat, sibutramine works by suppressing appetite; its efficacy, however, was similar to that of orlistat in the identified clinical trials. Orlistat was associated primarily with gastrointestinal side effects. Use of orlistat was associated with minimal drug interactions, except with cyclosporine, with which it should not be taken. Sibutramine was also well tolerated, although it may cause dry mouth, anorexia, and insomnia, and should be used with caution in patients at risk for cardiovascular disease.

CONCLUSIONS

Orlistat and sibutramine demonstrated a favorable efficacy and safety profile in randomized controlled trials. Current evidence supports their use as adjuncts to lifestyle modifications in the treatment of obesity.

Authors+Show Affiliations

Department of Medicine and Therapeutics, Division of Clinical Pharmacology, The Chinese University of Hong Kong, The Prince of Wales Hospital, Shatin, Hong Kong. wilson_leung@cuhk.edu.hkNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

12637112

Citation

Leung, Wilson Y S., et al. "Weight Management and Current Options in Pharmacotherapy: Orlistat and Sibutramine." Clinical Therapeutics, vol. 25, no. 1, 2003, pp. 58-80.
Leung WY, Thomas GN, Chan JC, et al. Weight management and current options in pharmacotherapy: orlistat and sibutramine. Clin Ther. 2003;25(1):58-80.
Leung, W. Y., Thomas, G. N., Chan, J. C., & Tomlinson, B. (2003). Weight management and current options in pharmacotherapy: orlistat and sibutramine. Clinical Therapeutics, 25(1), 58-80.
Leung WY, et al. Weight Management and Current Options in Pharmacotherapy: Orlistat and Sibutramine. Clin Ther. 2003;25(1):58-80. PubMed PMID: 12637112.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Weight management and current options in pharmacotherapy: orlistat and sibutramine. AU - Leung,Wilson Y S, AU - Thomas,G Neil, AU - Chan,Juliana C N, AU - Tomlinson,Brian, PY - 2003/3/15/pubmed PY - 2003/5/20/medline PY - 2003/3/15/entrez SP - 58 EP - 80 JF - Clinical therapeutics JO - Clin Ther VL - 25 IS - 1 N2 - BACKGROUND: Chronic obesity is associated with various cardiovascular disorders, including diabetes, dyslipidemia, and hypertension. Pharmacotherapy with antiobesity agents is an important management strategy in conjunction with lifestyle interventions. OBJECTIVE: This article describes the pharmacologic management of obesity, concentrating on orlistat and sibutramine. METHODS: Relevant articles were identified through a MEDLINE search (1966-February 2002) using the terms obesity, overweight, weight loss, antiobesity drugs, orlistat, and sibutramine. The search for efficacy trials was limited to randomized controlled studies of >6 months' duration. Also included in the review were relevant references cited in the bibliographies of identified articles, news reports, and the authors' own data. RESULTS: Orlistat reduces fat absorption by inhibiting gastrointestinal lipases. In randomized, controlled trials of up to 2 years' duration, orlistat plus a hypocaloric diet produced significantly greater weight loss than placebo (P < 0.001). In the maintenance phase, patients taking orlistat had less weight regain than did placebo recipients. The weight reduction with orlistat was also associated with a significant improvement in control of cardiovascular risk factors (P < 0.05). Unlike orlistat, sibutramine works by suppressing appetite; its efficacy, however, was similar to that of orlistat in the identified clinical trials. Orlistat was associated primarily with gastrointestinal side effects. Use of orlistat was associated with minimal drug interactions, except with cyclosporine, with which it should not be taken. Sibutramine was also well tolerated, although it may cause dry mouth, anorexia, and insomnia, and should be used with caution in patients at risk for cardiovascular disease. CONCLUSIONS: Orlistat and sibutramine demonstrated a favorable efficacy and safety profile in randomized controlled trials. Current evidence supports their use as adjuncts to lifestyle modifications in the treatment of obesity. SN - 0149-2918 UR - https://www.unboundmedicine.com/medline/citation/12637112/Weight_management_and_current_options_in_pharmacotherapy:_orlistat_and_sibutramine_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0149291803900099 DB - PRIME DP - Unbound Medicine ER -